Abstract:

Release Date:                                          January 1, 2010
Expiration Date:                                       December 31, 2010
Estimated time to complete activity:   1 hour

Sponsors:

This activity is jointly sponsored by Postgraduate Institute for Medicine and IMPACt, Inc.

Contact Postgraduate Institute for Medicine

Commercial Support:

This activity is supported by an educational grant from Eli Lilly and Company.

Description:

“The Maintenance Therapy Debate in Advanced Lung Cancer” will discuss current evidence as well as on-going research into the considerations for immediate second line therapy in advanced NSCLC.  In addition, a case study will be presented so that the data can be interpreted in a clinical context. The goal is to help clarify decision making regarding maintenance therapy.

Learning Objectives:

Upon completion of this activity, participants will be able to:

1. Describe the clinically significant outcomes including PFS, OS, QoL and toxicities for recent maintenance therapy trials in advanced NSCLC
2. Discuss the factors to be considered when considering maintenance therapy for a patient including QoL considerations vs. potential efficacy benefits
3. Apply current maintenance therapy data to clinical decision making as illustrated by the case studies

Target Audience:

This activity has been designed to meet the educational needs of medical oncologists involved in the care of patients with lung cancer.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and IMPACt, Inc.  PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation:

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Agenda:

Introduction/Overview
- Review the current state of the art

Case study

Review the maintenance therapy data
- Pemetrexed
- Maintenance docetaxel [Fidias]
- ATLAS
- SATURN
- Ongoing trials/Future Directions

The “Debate”
- Arguments against maintenance therapy

Faculty:

Corey J. Langer, MD (Course Director)
Professor, Department of Medicine
Director of the Thoracic Oncology Program
University of Pennsylvania

Nasser H. Hanna, MD
Associate Professor
Department of Medicine
Division of Hematology/Oncology
Indiana University School of Medicine

Chandra P. Belani, MD
Miriam Beckner Professor of Medicine
Penn State College of Medicine
Deputy Director,
Penn State Cancer Institute

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Corey J. Langer, MD, Course Director
Consulting fees:  Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Imclone, OSI, Sanofi-Aventis
Speakers’ Bureau:  Bristol-Myers Squibb, Eli Lilly and Company, Genentech,  Imclone, OSI, Sanofi-Aventis
 
Chandra P. Belani, MD
Consulting fees:  Eli Lilly and Company, Genentech, Sanofi-Aventis
 
Nasser H. Hanna, MD
Consulting fees:  Celgene, Merck
Research grants:  AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company,  Genentech, Pfizer

Planners and Managers

The following planners and managers, Linda Graham, RN, BSN, BA, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kirkwood, RN, BSN, Jan Schultz, RN, MSN, CCMEP and Scott McMahon hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity.

Archived Program:

You must login to view program.